SCHEDULE: Horton Capital Discloses 6% Stake in Myomo, Inc.

Horton Capital Partners has acquired a 6% stake in Myomo, Inc. and secured a board seat for Joseph M. Manko, Jr.

Summary

• Horton Capital Partners Fund, LP has acquired 2,309,775 shares of Myomo, Inc., representing a 6.0% ownership stake.
• The investment was made based on the belief that the shares were undervalued.
• Joseph M. Manko, Jr. was appointed to the Myomo, Inc. Board of Directors effective May 9, 2026.
• The reporting persons have submitted a shareholder proposal to declassify the Board of Directors to allow for annual director elections.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while activist involvement often signals potential for value creation, it also introduces short-term uncertainty regarding corporate strategy.

Positives

• Active engagement by a significant shareholder to potentially increase long-term value.
• Direct representation on the Board of Directors by the lead investor.
• The investor views the current share price as an attractive entry point.

Negatives

• Potential for future friction between the new board member and existing management regarding strategic direction.
• The filing indicates the investor may seek to influence or change the company's capital structure or business strategy.

Risks

• Market volatility associated with activist investor involvement.
• Uncertainty regarding the outcome of the proposed board declassification.
• Potential for future divestment or hedging activities by the reporting persons.

Future Outlook

The reporting persons intend to review their investment on a continuing basis and may engage in discussions with management regarding business strategy, capital allocation, and corporate governance to increase shareholder value.

Management Comments

• The Reporting Persons believe the Shares were undervalued and represented an attractive investment opportunity.
• The Reporting Persons may take steps seeking to bring about changes to increase shareholder value.

Industry Context

StockSavvy.ai notes that this move is consistent with broader trends in the medical device sector where activist investors are increasingly targeting small-cap companies to drive operational efficiency and governance reforms.

Comparison to Industry Standards

• The 6% stake is a standard threshold for triggering Schedule 13D filings in the U.S. market.
• The push for board declassification is a common governance reform sought by institutional investors to increase board accountability.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• None disclosed.

Stakeholder Impact

• Shareholders may see increased focus on value creation and governance reforms.
• Management may face increased scrutiny regarding capital allocation and strategic direction.

Next Steps

• Consideration of the shareholder proposal at the 2026 Annual Meeting of Stockholders.
• Ongoing monitoring of the investment by Horton Capital Partners.
• Potential future discussions between the Board and the new director regarding strategic direction.

Key Dates

Recommendation

The entry of an activist investor often leads to short-term price volatility. Investors should hold until the company's response to the board declassification proposal and the new director's influence on strategy becomes clearer.

Keywords

Myomo, Horton Capital, Activist Investor, Schedule 13D, Corporate Governance, Board Appointment